4.2.2 Antipsychotic depot injections

Depixol®

(Flupentixol decanoate)

  • Injection 20mg/ml (£2.54 = 2ml ampoule)
  • Concentrate injection 100mg/ml (£6.25 = 1ml ampoule)
  • Low-Volume injection 200mg/ml (£9.76 = 1ml ampoule)

Indications

Notes

  1. Please prescribe by brand to avoid confusion
  2. Refer to individual shared care guidelines
Haldol®

(Haloperidol decanoate)

  • Injection 50mg/ml (£3.81 = 1ml ampoule)
  • Injection 100mg/ml (£5.05 = 1ml ampoule)

Indications

Notes

  1. Refer to individual shared care guidelines
Clopixol®

(Zuclopenthixol decanoate)

  • Injection 200mg/ml (£3.15 = 1ml ampoule)
  • Conc. injection 500mg/ml (£3.72 = 1ml ampoule)

Indications

Notes

  1. Please prescribe by brand to avoid confusion
  2. Refer to individual shared care guidelines
Abilify Maintena®

(Aripiprazole)

  • Prolonged release injection 300mg, 400mg

Indications

Notes

  1. The commissioning of aripiprazole long-acting (depot) injection is accepted in Devon for the treatment of patients with schizophrenia who are non-adherent to antipsychotic medication or first generation antipsychotic depot injections are not clinically appropriate (see Commissioning Policy for more details)
Zypadhera®

(Olanzapine embonate monohydrate)

  • Prolonged release injection 210mg, 300mg, 405mg

Indications

Notes

  1. Olanzapine long-acting injection is associated with post-injection syndrome. Olanzapine should only be given in health-care facilities where administration of the injection and observation of patients post-injection can be undertaken safely and for at least three hours. The three-hour observation period should be extended as clinically appropriate for patients who exhibit any signs or symptoms consistent with olanzapine overdose. Olanzapine should only be administered by healthcare professionals trained in the appropriate injection technique. Training materials are available at: https://www.zypadhera.co.uk/SignIn.aspx
  2. The commissioning of olanzapine long-acting (depot) injection is accepted in Devon for the treatment of patients with schizophrenia who are non-adherent to antipsychotic medication or first generation antipsychotic depot injections are not clinically appropriate (see Commissioning Policy for more details)
Xeplion®

(Paliperidone palmitate)

  • Prolonged release injection available as prefilled syringe: 50mg, 75mg, 100mg, 150mg

Indications

Notes

  1. Please prescribe by brand to avoid confusion
  2. The commissioning of paliperidone long-acting (depot) injection is accepted in Devon for the treatment of patients with schizophrenia who are non-adherent to antipsychotic medication or first generation antipsychotic depot injections are not clinically appropriate (see Commissioning Policy for more details)
Trevicta®

(Paliperidone palmitate)

  • 3-monthly prolonged release injection available as prefilled syringe: 175mg, 263mg, 350mg, 525mg

Indications

Notes

  1. Please prescribe by brand to avoid confusion
  2. The commissioning of paliperidone long-acting (depot) injection is accepted in Devon for the treatment of patients with schizophrenia who are non-adherent to antipsychotic medication or first generation antipsychotic depot injections are not clinically appropriate (see Commissioning Policy for more details)

 

Home > Formulary > Chapters > 4. Central Nervous System > 4.2 Drugs used in psychoses and related disorders > 4.2.2 Antipsychotic depot injections

 

  • First line
  • Second line
  • Specialist
  • Hospital